Medscape

NCCN 2009: Recommendations on Managing Skin Toxicities With EGFR Inhibitors

March 17, 2009 (Hollywood, Florida) — The management of dermatologic toxicities associated with the use of epidermal growth-factor-receptor (EGFR) inhibitors in cancer patients is in a nascent stage ...
Cure Today

HT-001 Improves Skin Side Effects From EGFR Treatments

ng/mL; Cavg 1.90 to 3.36 ng/mL; Cmax 3.07 to 4.56 ng/mL) while remaining a small fraction of oral comparator exposure (<0.5%). Symptom severity improved and appeared sustained. No serious adverse ...
Medscape

Novel Topical BRAF Inhibitor Shows Promise for Managing EGFR Inhibitor–Induced Acneiform Rash

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...
ascopubs.org

Exploration of different EGFR scores and their relationship with prognosis in patients with urothelial carcinoma with squamous differentiation.

Safety of angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients with bladder and upper tract malignancies undergoing platinum-based chemotherapy: A ...
ascopubs.org

Incidence and Prognostic Values in Human Epidermal Growth Factor Receptor 2-Low Expression Metastatic Breast Cancer in Southeast Asian Population: A 10-Year Retrospective Study

Of the 491 patients, 21.2% had HER2-low expression, 30% had HER2 overexpression, and 50% had HER2-negative expression. Among the hormone receptor (HR)–positive patients, 34% had HER2-low expression; ...